ITGA2 and glioblastoma: This is due to the fact that these IgG-LP-treated GBM cells exhibit a 1.3–1.9 fold higher motility speed than ITGA2 antibody-blocked GBM cells (Fig. 4c), leading to a 24–47% increased migration distance.